Beam Therapeutics (NASDAQ: BEAM) net income
Beam Therapeutics reported a net loss of $80.0m for fiscal 2025; in fiscal 2024 it reported a net loss of $376.7m. Earnings per share were −$0.81.
Beam Therapeutics's best year of the last 7 was fiscal 2019. It reported a loss in 7 of those 7 years.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Net income by fiscal year
| Fiscal year | Net income | Change | Net margin | Earnings per share |
|---|---|---|---|---|
| 2025 | −$80.0m | — | −57.2% | −$0.81 |
| 2024 | −$376.7m | — | −593.1% | −$4.58 |
| 2023 | −$132.5m | — | −35.1% | −$1.72 |
| 2022 | −$289.1m | — | −474.5% | −$4.13 |
| 2021 | −$370.6m | — | −714.9% | −$5.77 |
| 2020 | −$194.6m | — | −810,800.0% | −$4.19 |
| 2019 | −$78.3m | — | −435,144.4% | −$14.05 |
The change compares each fiscal year with the one before and is not calculated when the previous year closed with a loss. Net margin is net income over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Beam Therapeutics net income compared with its sector
By net income for its latest fiscal year, Beam Therapeutics ranks 312th of the 501 US health care companies with a page on Celsmar. The sector median net margin is −6.2%; that of Beam Therapeutics, −57.2%.
| Rank | Company | Net income | Net margin |
|---|---|---|---|
| 310th | Corbus Pharmaceuticals | −$78.5m | — |
| 311th | X4 Pharmaceuticals | −$79.2m | −225.6% |
| 312th | Beam Therapeutics | −$80.0m | −57.2% |
| 313th | CAMP4 Therapeutics | −$80.4m | −2,298.5% |
| 314th | STAAR Surgical | −$80.4m | −33.6% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the net income of Beam Therapeutics
- How much did Beam Therapeutics earn in fiscal 2025?
- Beam Therapeutics reported a net loss of $80.0m for fiscal 2025. In fiscal 2024 it reported a net loss of $376.7m.
- What are the earnings per share of Beam Therapeutics?
- They were −$0.81 in fiscal 2025, compared with −$4.58 in fiscal 2024.
- Where does Beam Therapeutics rank in its sector by net income?
- It ranks 312th of the 501 US health care companies with a page on Celsmar, by net income for its latest fiscal year.
- Where do the figures for Beam Therapeutics come from?
- From the annual report (Form 10-K) that Beam Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Beam Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Beam Therapeutics: the Beam Therapeutics page · annual accounts · revenue · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.